Literature DB >> 22090195

Clopidogrel and PPI interaction: clinically relevant or not?

Robert W Harrison1, Kenneth W Mahaffey.   

Abstract

Proton pump inhibitors and clopidogrel are commonly prescribed medications, both alone and in combination. In January of 2009 the US Food and Drug Administration and the European Medicines Agency issued warnings with regard to the concomitant use of clopidogrel and proton pump inhibitors. Later that year, these warnings were limited to the proton pump inhibitor omeprazole. These warnings were largely based on in-vitro studies and observational analyses suggesting decreased efficacy of clopidogrel in the presence of proton pump inhibitors. Recent literature has suggested there may not be a clinically meaningful interaction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22090195     DOI: 10.1007/s11886-011-0233-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  53 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

2.  Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications.

Authors:  Kam-Chuen Lai; Kent-Man Chu; Wai-Mo Hui; Benjamin Chun-Yu Wong; Wai-Ka Hung; Ching-Kong Loo; Wayne Hsing-Ching Hu; Annie On-On Chan; Ka-Fai Kwok; Tang-Tat Fung; John Wong; Shiu-Kum Lam
Journal:  Clin Gastroenterol Hepatol       Date:  2006-06-22       Impact factor: 11.382

3.  Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.

Authors:  J-S Hulot; G Wuerzner; C Bachelot-Loza; M Azizi; A Blanchard; S Peyrard; C Funck-Brentano; P Gaussem
Journal:  J Thromb Haemost       Date:  2009-12-21       Impact factor: 5.824

4.  Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.

Authors:  Fei-Yuan Hsiao; C Daniel Mullins; Yu-Wen Wen; Weng-Foung Huang; Pei-Fen Chen; Yi-Wen Tsai
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-08-08       Impact factor: 2.890

5.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Authors:  Francis K L Chan; Jessica Y L Ching; Lawrence C T Hung; Vincent W S Wong; Vincent K S Leung; Nelson N S Kung; Aric J Hui; Justin C Y Wu; Wai K Leung; Vivian W Y Lee; Kenneth K C Lee; Yuk T Lee; James Y W Lau; Ka F To; Henry L Y Chan; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

6.  Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.

Authors:  Suksiri Siriswangvat; Nakarin Sansanayudh; Surakit Nathisuwan; Duangchit Panomvana
Journal:  Circ J       Date:  2010-08-21       Impact factor: 2.993

7.  Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.

Authors:  Wayne A Ray; Katherine T Murray; Marie R Griffin; Cecilia P Chung; Walter E Smalley; Kathi Hall; James R Daugherty; Lisa A Kaltenbach; C Michael Stein
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

Review 8.  Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

Authors:  J M Siller-Matula; B Jilma; K Schrör; G Christ; K Huber
Journal:  J Thromb Haemost       Date:  2010-12       Impact factor: 5.824

9.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

10.  Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Authors:  Peter B Berger; Deepak L Bhatt; Valentin Fuster; P Gabriel Steg; Keith A A Fox; Mingyuan Shao; Danielle M Brennan; Werner Hacke; Gilles Montalescot; Steven R Steinhubl; Eric J Topol
Journal:  Circulation       Date:  2010-06-01       Impact factor: 29.690

View more
  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

Authors:  Xi-Ling Jiang; Snehal Samant; Lawrence J Lesko; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 2.  Proton pump inhibitors: impact on glucose metabolism.

Authors:  Diana Boj-Carceller
Journal:  Endocrine       Date:  2012-08-12       Impact factor: 3.633

3.  Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.

Authors:  Ahmed Awaisu; Fatima Hamou; Lylia Mekideche; Nisrine El Muabby; Ahmed Mahfouz; Shaban Mohammed; Ahmad Saad
Journal:  Int J Clin Pharm       Date:  2016-01-09

Review 4.  Proton pump inhibitors and clopidogrel: an association to avoid?

Authors:  Emilia D'Ugo; Serena Rossi; Raffaele De Caterina
Journal:  Intern Emerg Med       Date:  2013-09-13       Impact factor: 3.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.